

Veracyte to Present at the Cantor Fitzgerald Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <u>Veracyte, Inc.</u> (NASDAQ: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2017 at 2:15 p.m. Eastern Time in New York, NY.

The live webcast from the Cantor Fitzgerald conference and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. The replay of the webcast will be available shortly after conclusion of the presentation and archived on the company's website for 90 days following the presentation.

About Veracyte

Veracyte (NASDAQ: VCYT) is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a \$2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit <u>www.veracyte.com</u> and follow the company on Twitter (@veracyte).

Veracyte and the Veracyte logo are trademarks of Veracyte, Inc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170913005481/en/

Veracyte, Inc. Media: Tracy Morris, 650-380-4413 tracy.morris@veracyte.com or Investors: Jackie Cossmon, 650-243-6371 jackie@veracyte.com

Source: Veracyte, Inc.

News Provided by Acquire Media